Endeavor

Cell Therapy Changed Cancer Care. Now Researchers Want to Make It Work Better

Moffitt brought together experts from across the country to explore ways to make cell therapies more durable and effective for more patients

Inside the Breakthroughs That Changed Melanoma Care

Moffitt researchers helped drive decades of FDA approvals that transformed patient outcomes

Defining Surgical Success for TIL Therapy in Metastatic Melanoma

Despite FDA approval to treat metastatic melanoma in 2024, data regarding optimal surgical approach is limited

Immunotherapy Pioneer Steven Rosenberg Reflects on Past Breakthroughs and Future Promise

Legendary researcher connects immunotherapy’s origins to its future at Moffitt

TIL Therapy Research Expanded to Bladder Cancer

Almost half of patients enrolled in a Moffitt trial responded to the cellular immunotherapy

Can Hybrid Immunotherapy Improve Solid Tumor Treatment?

Moffitt researchers test CAR-TIL cells combining tumor navigation and targeted attack

Study Looks To Improve TIL Therapy for Advanced Melanoma

TIL therapy can be used to treat advanced melanoma when patients do not respond to standard treatment options

Moffitt Launches Immunotherapy Podcast

Monthly series highlights visionaries in immunotherapy and the breakthroughs that are transforming lives

Moffitt Study Shows New Immune Boost Could Expand Access to Cancer Immunotherapy

Adding a natural protein improves the speed and success of TIL manufacturing, potentially benefiting more patients